FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024192220> ?p ?o ?g. }

• W2024192220 endingPage "1553" @default.
• W2024192220 startingPage "1542" @default.
• W2024192220 abstract "Although pemetrexed, a potent thymidylate synthase (TS) inhibitor, enhances the cytoytoxic effect of platinum compounds against malignant pleural mesothelioma (MPM), novel combinations with effective targeted therapies are warranted. To this end, the current study evaluates new targeted agents and their pharmacological interaction with carboplatin-pemetrexed in human MPM cell lines.We treated H2052, H2452, H28 and MSTO-211H cells with carboplatin, pemetrexed and targeted compounds (gefitinib, erlotinib, sorafenib, vandetanib, enzastaurin and ZM447439) and evaluated the modulation of pivotal pathways in drug activity and cancer cell proliferation.Vandetanib emerged as the compound with the most potent cytotoxic activity, which interacted synergistically with carboplatin and pemetrexed. Drug combinations blocked Akt phosphorylation and increased apoptosis. Vandetanib significantly downregulated epidermal growth factor receptor (EGFR)/Erk/Akt phosphorylation as well as E2F-1 mRNA and TS mRNA/protein levels. Moreover, pemetrexed decreased Akt phosphorylation and expression of DNA repair genes. Finally, most MPM samples displayed detectable levels of EGFR and TS, the variability of which could be used for patients' stratification in future trials with vandetanib-pemetrexed-carboplatin combination.Vandetanib markedly enhances pemetrexed-carboplatin activity against human MPM cells. Induction of apoptosis, modulation of EGFR/Akt/Erk phosphorylation and expression of key determinants for pemetrexed and carboplatin activity contribute to this synergistic interaction, and, together with the expression of these determinants in MPM samples, warrant further clinical investigation." @default.
• W2024192220 created "2016-06-24" @default.
• W2024192220 creator A5034973024 @default.
• W2024192220 creator A5035296183 @default.
• W2024192220 creator A5041229832 @default.
• W2024192220 creator A5041255789 @default.
• W2024192220 creator A5044707786 @default.
• W2024192220 creator A5062532607 @default.
• W2024192220 creator A5063509465 @default.
• W2024192220 creator A5070833456 @default.
• W2024192220 creator A5081278297 @default.
• W2024192220 creator A5082045927 @default.
• W2024192220 creator A5082701305 @default.
• W2024192220 creator A5083969171 @default.
• W2024192220 creator A5087772154 @default.
• W2024192220 date "2011-10-04" @default.
• W2024192220 modified "2023-10-10" @default.
• W2024192220 title "Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin" @default.
• W2024192220 cites W1975180009 @default.
• W2024192220 cites W1989131755 @default.
• W2024192220 cites W1989410548 @default.
• W2024192220 cites W2004114072 @default.
• W2024192220 cites W2004445514 @default.
• W2024192220 cites W2005868479 @default.
• W2024192220 cites W2013060968 @default.
• W2024192220 cites W2013661099 @default.
• W2024192220 cites W2014467256 @default.
• W2024192220 cites W2016546844 @default.
• W2024192220 cites W2021432766 @default.
• W2024192220 cites W2031365579 @default.
• W2024192220 cites W2035549030 @default.
• W2024192220 cites W2041710964 @default.
• W2024192220 cites W2046022946 @default.
• W2024192220 cites W2052111639 @default.
• W2024192220 cites W2054673942 @default.
• W2024192220 cites W2064483038 @default.
• W2024192220 cites W2067837009 @default.
• W2024192220 cites W2083215308 @default.
• W2024192220 cites W2084098878 @default.
• W2024192220 cites W2099462532 @default.
• W2024192220 cites W2100772777 @default.
• W2024192220 cites W2101019384 @default.
• W2024192220 cites W2101087680 @default.
• W2024192220 cites W2102590541 @default.
• W2024192220 cites W2102627969 @default.
• W2024192220 cites W2107666024 @default.
• W2024192220 cites W2109841006 @default.
• W2024192220 cites W2113954569 @default.
• W2024192220 cites W2116751548 @default.
• W2024192220 cites W2116864064 @default.
• W2024192220 cites W2121728733 @default.
• W2024192220 cites W2122185071 @default.
• W2024192220 cites W2122284070 @default.
• W2024192220 cites W2123555204 @default.
• W2024192220 cites W2127497086 @default.
• W2024192220 cites W2130024368 @default.
• W2024192220 cites W2134964659 @default.
• W2024192220 cites W2140714376 @default.
• W2024192220 cites W2142066824 @default.
• W2024192220 cites W2145842917 @default.
• W2024192220 cites W2148716917 @default.
• W2024192220 cites W2148873089 @default.
• W2024192220 cites W2151229627 @default.
• W2024192220 cites W2152241526 @default.
• W2024192220 cites W2152529513 @default.
• W2024192220 cites W2152779325 @default.
• W2024192220 cites W2154590917 @default.
• W2024192220 cites W2169449084 @default.
• W2024192220 cites W2265954609 @default.
• W2024192220 cites W2340465532 @default.
• W2024192220 cites W2406920217 @default.
• W2024192220 cites W900569881 @default.
• W2024192220 doi "https://doi.org/10.1038/bjc.2011.400" @default.
• W2024192220 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3242521" @default.
• W2024192220 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21970874" @default.
• W2024192220 hasPublicationYear "2011" @default.
• W2024192220 type Work @default.
• W2024192220 sameAs 2024192220 @default.
• W2024192220 citedByCount "38" @default.
• W2024192220 countsByYear W20241922202012 @default.
• W2024192220 countsByYear W20241922202013 @default.
• W2024192220 countsByYear W20241922202014 @default.
• W2024192220 countsByYear W20241922202015 @default.
• W2024192220 countsByYear W20241922202016 @default.
• W2024192220 countsByYear W20241922202017 @default.
• W2024192220 countsByYear W20241922202018 @default.
• W2024192220 countsByYear W20241922202019 @default.
• W2024192220 countsByYear W20241922202020 @default.
• W2024192220 countsByYear W20241922202022 @default.
• W2024192220 countsByYear W20241922202023 @default.
• W2024192220 crossrefType "journal-article" @default.
• W2024192220 hasAuthorship W2024192220A5034973024 @default.
• W2024192220 hasAuthorship W2024192220A5035296183 @default.
• W2024192220 hasAuthorship W2024192220A5041229832 @default.
• W2024192220 hasAuthorship W2024192220A5041255789 @default.
• W2024192220 hasAuthorship W2024192220A5044707786 @default.
• W2024192220 hasAuthorship W2024192220A5062532607 @default.
• W2024192220 hasAuthorship W2024192220A5063509465 @default.

• next